Meeting
2022 ASCO Genitourinary Cancers Symposium
Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.
Authors
Ajeet Gajra
Cardinal Health, Dublin, OH
Ajeet Gajra , Yolaine Jeune-Smith , Ulka N. Vaishampayan , Skyler Rupard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 355)
DOI
10.1200/JCO.2022.40.6_suppl.355
Abstract #
355
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
First Author: Pratik Rane
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
First Author: James M. G. Larkin
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald